ConductScience.org, home

Gene · 1201

CLN3: CLN3 lysosomal/endosomal transmembrane protein, battenin

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. CLN3: CLN3 lysosomal/endosomal transmembrane protein, battenin. Genes, record 1201. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/1201

On this page

Gene

Symbol
CLN3
HGNC
Name
CLN3 lysosomal/endosomal transmembrane protein, battenin
HGNC
NCBI Gene ID
1201
NCBI Gene
HGNC ID
HGNC:2074
HGNC
Ensembl
ENSG00000188603
NCBI Gene
Aliases
BTN1, BTS, JNCL, RP101, SLC29B1
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
Q13286Battenin4380Ensembl, GeneID, HGNC

Source UniProt

Patents93

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
JP 2026515744 A2026-05-19247Q13286Espacenet
JP 2026067851 A2026-04-21257Q13286Espacenet
EP 4704920 A12026-03-1114Q13286Espacenet
EP 4641201 A22025-10-297783Q13286Espacenet
JP 2025138648 A2025-09-251Q13286Espacenet
JP 2025529142 A2025-09-041023Q13286Espacenet
US 12371689 B22025-07-291023Q13286Espacenet
JP 2025517969 A2025-06-127783Q13286Espacenet
US 12297447 B22025-05-131Q13286Espacenet
JP 2025514710 A2025-05-0914Q13286Espacenet

1 to 10 of 93

See all 93 patents

Drugs0

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

None in this release.

Trials0

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

None in this release.

NIH grants736

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleCLN3 papersNewest fiscal year
ZICMH002961Neurodevelopmental and Behavioral Phenotyping52025
P50HD103536University of Rochester Intellectual and Developmental Disabilities Research Center42025
R01EY022356Molecular Basis of Human Visual System Disorders32025
ZIAHD000910Childhood Neurodegenerative Lysosomal Storage Disorders32025
ZIAHD009001Research Investigations of Cellular Stress in Development and Diseases32025
ZIAHL000140Lysosomal Diseases32025
ZIATR000018Drug Repurposing Screening for Rare and Neglected Diseases32025
P01AG019724Frontotemporal Dementia: Genes, Images, and Emotions22025
P20GM103442ND INBRE Health & the Environment22025
P30CA008748Cancer Center Support Grant22025

1 to 10 of 736Source NIH's project files

See all 736 nih grants

Papers1,287

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
Key Reaction Mechanisms on ZnO during Vulcanization: A Study Based on Density Functional Theory Calculations and Supporting Experiments.ACS Omega202642729752PubTator, text miningPubMed
A 3D human retina model reveals a non-cell-autonomous and non-neuronal mechanism of photoreceptor loss in a lysosomal storage disorder.Sci Transl Med202642647598PubTator, text miningPubMed
High-resolution promoter interaction analysis implicates genes involved in activation of type 3 innate lymphoid cells in immune disease risk.Nat Genet202642552386PubTator, text miningPubMed
Thapsigargin-induced autophagic flux impairment and inflammation are potentiated by CLN3 deficiency and alleviated by 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) in human ARPE-19 cells.Biochem Biophys Res Commun202642308764PubTator, text miningPubMed
Behavioral and emotional symptoms and quality of life in a national sample of individuals with CLN3 Batten disease.Orphanet J Rare Dis202642277918PubTator, text miningPubMed
Cognitive test performance in CLN3 Disease is associated with the CLN3 Staging System (CLN3SS).medRxiv202642238422PubTator, text miningPubMed
Mania in Juvenile Neuronal Ceroid Lipofuscinosis (CLN3 Disease): A Rare Neuropsychiatric Presentation in an Adolescent.J Child Neurol202642153457PubTator, text miningPubMed
PPARα and RXRα in the regulation of neuronal ceroid lipofuscinosis genes: implications for Batten disease therapy.NeuroImmune Pharm Ther202642146023PubTator, text miningPubMed
Toward Early Diagnosis and Therapeutic Discovery in CLN3 Disease: A Computational Biomarker Discovery Framework.medRxiv202642145637PubTator, text miningPubMed
Modeling CLN3 Batten disease in astrocytes reveals alterations in mitochondria homeostasis, fatty acid metabolism and oxidative stress response.J Biomed Sci202642129767PubTator, text miningPubMed

1 to 10 of 1,287

See all 1,287 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/1201

GET https://conductscience.org/api/genes/v1/1201/patents?page=2